Athanasios Tsianakas

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells

Georg Varga, Jan Ehrchen, Athanasios Tsianakas et al. · Journal of Leukocyte Biology · 2008 · 151 citations · Full text

Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis

Thomas Werfel, Gary Layton, Michael Yeadon et al. · Journal of Allergy and Clinical Immunology · 2018 · 129 citations

Drug Hypersensitivity, Allergy, Atopic Dermatitis +7

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study

Karoline Krause, Athanasios Tsianakas, Nicola Wagner et al. · Journal of Allergy and Clinical Immunology · 2016 · 100 citations · Full text

Allergy, Systemic Scleroderma, Placebo-controlled Study +3

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Christine Bodemer, Andrzej Kaszuba, Külli Kingo et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 92 citations · Full text